All In Biotech

Drug Trial Radar · NCT00704665

Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma

A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma

Last checked: Nov 20, 2026Latest source record: Jun 25, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Dec 1998

Primary completion

Dec 2001

Study completion Dec 2001

Sponsor

Lead sponsor
University of Medicine and Dentistry of New JerseyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, Los Angeles; Boston University; University of Chicago; UConn Health; Johns Hopkins University; University of Pittsburgh; Medical University of South Carolina; Stanford University; Georgetown University; University of California, San Diego; Wayne State University; University of Colorado, Denver; Medical College of Wisconsin
First posted
Jun 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in pregnancy. Study is designed to see if skin improvement and improvement in functional ability can be achieved.

Conditions

  • Systemic Sclerosis

Interventions

  • RelaxinDrug

    10 ug/kg/day or 25 ug/kg/day

  • RelaxinDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRSSTime frame: baseline, weeks 4,12, and 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.